Out-Licensing Manager
About the job
- A bachelor's degree in Pharmacy, Life Sciences, or a related field.
- A minimum of 8–10 years of experience in pharmaceutical business development or licensing, with a focus on Europe.
- Proven success in executing out-licensing deals and managing complex negotiations.
- A strong understanding of the European pharmaceutical value chain, regulatory frameworks, and commercial models.
- Business development, negotiation, and alliance management skills.
- Strong business acumen and technical expertise in the pharmaceutical industry.
- Identify, evaluate, and prioritize out-licensing opportunities across Europe for key therapeutic areas.
- Develop and manage strategic relationships with partners, distributors, and regional stakeholders.
- Lead full-cycle deal management, from opportunity scouting to contract execution and ongoing collaboration.
- Maintain and manage a pipeline of prospects aligned with EVA Pharma's market access strategy.
- Collaborate with Research and Development, Regulatory, and Supply Chain teams on licensing readiness and dossier preparation.
- Lead commercial negotiations and ensure optimal terms, compliance, and partnership value.
- Partner with Legal, Finance, and Operations on contract execution, product registrations, and post-deal management.
- An MBA or postgraduate qualification in Business or International Management.
About the company
EVA Pharma develops and manufactures affordable medicines for global markets, focusing on 12 therapeutic areas such as anti-infectives, metabolic health, oncology, and pediatrics. It operates four manufacturing facilities with a 5,000-strong team and produces over one million healthcare products daily. The company runs two regional research centers that use AI-driven prediction and mRNA R&D to develop biological products and first-of-its-kind capabilities in the Middle East and Africa. EVA Pharma distributes its products to more than 60 countries and seeks to expand access to high-quality medicines worldwide. Its differentiation comes from its scale, regional R&D capabilities, and commitment to sustainable access, aiming to meet pressing, unmet disease needs with reliable supply.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Al Sharikat, Egypt
Founded
1997
Get referred to Eva Pharma
See people who can refer or advise you
Simplify's Take
What believers are saying
- Egypt’s December 2024 insulin approval opens exportable manufacturing revenues and credibility with regulators.
- November 2025 EVA Pharma Oncology targets 22 million packs annually, with 11 more treatments planned.
- Access-heavy partnerships with Gilead, BeiGene, and Porton create multiple near-term revenue streams.
What critics are saying
- Gilead’s generic lenacapavir supply starts 2027, so execution delays destroy EVA Pharma’s moat.
- Oncology launches need Egypt market uptake; BRUKINSA, TEVIMBRA, and seven in-house products face entrenched competitors.
- Any FDA, EDA, or Gilead tech-transfer setback blocks EVA Pharma’s pivot into high-value biologics.
What makes Eva Pharma unique
- Egypt’s 2024 Lilly insulin approval proves EVA Pharma can localize complex biologics manufacturing.
- The 2024 Gilead lenacapavir license makes EVA Pharma Africa’s sole local generic producer.
- The 2025 BeiGene deal and 2025 Porton MOU extend EVA Pharma beyond generics into oncology and CAR-T.
Help us improve and share your feedback! Did you find this helpful?
Company News
The collaboration will combine Porton Advanced's capabilities in manufacturing viral vectors and cell therapies with EVA Pharma's expanding presence in the high-tech biopharmaceutical sector.
This milestone stems from the companies' collaboration to expand access to affordable insulin to one million people living with diabetes in low- to middle-income countries annually by 2030INDIANAPOLIS and CAIRO, Dec. 17, 2024 /PRNewswire/ -- The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the collaboration aims to deliver a sustainable supply of high-quality, affordable human and analog insulin to at least one million people annually living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa. This marks the first regulatory approval of EVA Pharma's insulin drug products, following Lilly and EVA Pharma's collaboration announcement in December 2022. Under this agreement, Lilly has been supplying its active pharmaceutical ingredient (API) for insulin to EVA Pharma at a significantly reduced price and providing pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges
In December 2022, Lilly announced an agreement with EVA Pharma to enhance sustainable access to affordable insulin in 56 low- and middle-income countries, mostly in Africa.
EVA Pharma is also developing its own COVID-19 vaccine and is pursuing further clinical research on next-generation vaccines.